Table 2.
Cardiometabolic phenotype & therapies
| 1st Quartile Lp(a) | Quartiles 2–4 Lp(a) | P | ||
|---|---|---|---|---|
| n | 85 | 255 | ~ | |
| insulinaemia | pmol.L−1 | 136 (93) | 100 (70) | 0.0014 |
| insulin sensitivity | % | 40 (26) | 62 (43) | < 0.0001 |
| hyperbolic product [B x S] | % | 22 (15) | 30 (20) | < 0.0001 |
| [B x S] loss rate | %.yr.−1 | 1.46 (0.65) | 1.27 (0.49) | 0.0149 |
| βCS - metformin - TZD | % | 37 - 76 - 7 | 45 - 71 - 3 | NS |
| DDP-4-I / GLP-1-RA | % | 15 | 29 | 0.0100 |
| insulin | % | 56 | 43 | 0.0442 |
| IU.day−1.kg−1 | 0.94 (0.86) | 0.70 (0.44) | NS | |
| ACE-I - ARB | % | 44–34 | 36–28 | NS |
| CCB - BB - diuretic | % | 33 - 34 - 46 | 29 - 42 - 34 | NS |
| aspirin | % | 55 | 54 | NS |
| anti-dyslipidemic drug(s) | % | 86 | 85 | NS |
| statin - ezetimibe | % | 76–13 | 81–13 | NS |
| fenofibrate | % | 36 | 19 | 0.0045 |
Results are expressed as means (1 SD) or proportions (%). ACE-I angiotensin-converting enzyme inhibitor ARB angiotensin II type −1 receptor (AT1) blocker, βCS beta-cell stimulant, BB beta-blockers, CCB calcium-channel blocker, DPP-4-I dipeptidyl peptidase type 4 inhibitor, GLP-1-RA glucagon-like peptide 1 receptor agonist, Lp(a) lipoprotein(a), TZD thiazolidinedione, NS not significant